![MindMed](https://pharmashots.com/public/default-image/default-730x400.png )
MindMed Receives US Patent for MM120 to Treat Generalized Anxiety Disorder
Shots:
- The USPTO has issued a new patent covering MM120 under development for generalized anxiety disorder (GAD). MM120 will proceed to P-III study for GAD in H2’24 and will be explored for other indications
- The patent (USPN 12,036,220) covers its formulation, manufacturing methods & treatment methods for MM120 orally disintegrating tablet (ODT), protecting it until 2041
- MM120 (lysergide D-tartrate) is a synthetic ergotamine acting as partial serotonin-2A receptors agonist, the formulation of which uses Catalent’s Zydis ODT fast-dissolve technology. MindMed secured exclusive rights of the technology for all lysergide forms across the US, UK, EU, Switzerland, Israel & Canada to treat various disorders
Ref: MindMed | Image: MindMed
Related News:- MindMed Reports the Results for MM120 in P-IIb Trial and Receives US FDA’s BTD for the Treatment of Generalized Anxiety Disorder (GAD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
![](https://pharmashots.com/public/images/Disha-2023-03-21-64199f99761c8.png)
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.